Core Viewpoint - The competition for the "king of drugs" title in the GLP-1 market is intensifying between Novo Nordisk and Eli Lilly, with Eli Lilly's GLP-1 drug tirzepatide significantly contributing to its revenue growth in 2025 [1][2]. Group 1: Eli Lilly's Financial Performance - Eli Lilly reported total revenue of $65.179 billion for the year 2025, a 44% increase year-over-year at constant exchange rates [1][2]. - The key driver of this growth was the GLP-1 drug tirzepatide, which generated $36.5 billion in revenue (approximately 253.4 billion RMB) [1][3]. - In Q4 2025, Eli Lilly's revenue reached $19.29 billion, a 43% year-over-year increase, with net profit soaring to $20.64 billion, up 95% [2]. Group 2: Market Dynamics and Competition - The GLP-1 market is currently dominated by Eli Lilly and Novo Nordisk, with combined revenues approaching $50 billion in 2024 [6]. - Eli Lilly's tirzepatide is positioned to capture both diabetes and obesity markets, with Zepbound's sales growth of 175% outpacing Mounjaro's growth in diabetes [1][2]. - Novo Nordisk's oral GLP-1 drug Wegovy has received FDA approval, intensifying competition in the market [7]. Group 3: Pricing and Future Outlook - Eli Lilly faces increasing pricing pressure, with both companies agreeing to lower prices for their GLP-1 drugs starting November 2025 [9]. - The global GLP-1 market is expected to see significant growth, with sales projected to exceed $17 billion by 2031, reflecting a compound annual growth rate of 15.6% from 2021 to 2031 [10]. - The competition is shifting from a "blue ocean" market to a more competitive landscape, with a focus on efficacy, convenience, pricing accessibility, and expanded indications [10].

中原期货研究咨询部 2026 第（24）期 发布日期：2026-02-05 | 中原期货研究咨询部 | 0371-58620081 | | --- | --- | | 0371-58620083 | | | 公司官方微信 | | 1 公司官方微信 中原期货研究咨询部 | 化工 | 主力合约 | 2026/2/5 | 2026/2/4 | 涨跌 | 涨跌幅/% | | --- | --- | --- | --- | --- | --- | | | | 8:00 | 15:00 | | | | | 焦煤 | 1,187.50 | 1,209.00 | -21.50 | -1.778 | | | 焦炭 | 1,753.00 | 1,770.00 | -17.0 | -0.960 | | | 天然橡胶 | 16,325.00 | 16,385.00 | -60.0 | -0.366 | | | 20号胶 | 13,260.00 | 13,300.00 | -40.0 | -0.301 | | | 塑料 | 6,867.00 | 6.918.00 | -51.0 | -0.737 | | | 聚丙烯PP | 6,759 ...

Market Overview - The Hong Kong stock market showed mixed performance with the Hang Seng Index closing at 23,831 points, down 145 points or 0.61% [1] - The market turnover decreased to 82.799 billion [1] - The net inflow of funds through the Hong Kong Stock Connect was 484 million, with Shanghai Stock Connect contributing 283 million and Shenzhen Stock Connect 201 million [1] Sector Performance - Energy and real estate sectors performed well, with coal-related assets rising due to supply constraints from Indonesia, leading to Yanzhou Coal Mining increasing over 10% and China Shenhua Energy rising over 5% [1] - Domestic property stocks also saw gains, with Shimao Group up over 14%, Sunac China up over 8%, Vanke up over 6%, and Yuexiu Property up over 6% [1] - Conversely, chip and tech stocks declined, with Shanghai Fudan down over 5%, Hua Hong Semiconductor down nearly 5%, and Tencent Holdings down nearly 4% [1] US Market Performance - The US stock market had mixed results, with the Dow Jones up 0.53%, while the S&P 500 and Nasdaq fell by 0.51% and 1.51% respectively [2] - Notable gainers included Amgen, which rose over 8%, and Nike, which increased by over 5% [2] - The tech sector faced challenges, with the Nasdaq China Golden Dragon Index down 1.95% and major chip stocks like AMD dropping over 17% [2] Investment Opportunities - The report emphasizes the importance of "technological self-reliance" and AI applications as key themes for future growth in the Hong Kong stock market, suggesting that leading companies in these sectors may see medium to long-term development opportunities [3] - It is recommended to focus on sectors supported by policies aimed at expanding domestic consumption, such as sports apparel and non-essential services [3] - The report highlights the continued value of Hong Kong stocks centered around Chinese assets, particularly in technology, consumer sectors, and undervalued state-owned enterprises [3] Company Highlights - ZTE Corporation (0763.HK) is noted for its comprehensive communication manufacturing capabilities, with a projected revenue of 121.299 billion for 2024, despite a slight decline [10] - The company maintains a high gross margin of 37.91% and is expected to see significant growth in its server and storage revenue, particularly in the AI computing sector [10] - Analysts predict ZTE's net profits for 2025 and 2026 to be 7.98 billion and 8.81 billion RMB respectively, indicating a relatively low valuation compared to its earnings potential [10]

Core Insights - The 2026 JPMorgan Healthcare Conference has highlighted significant trends in the biopharmaceutical industry, particularly in mergers and acquisitions (M&A) among multinational corporations (MNCs) [1] - Major acquisitions include Boston Scientific's $14.5 billion purchase of Penumbra and GSK's $2.2 billion acquisition of RAPT Therapeutics, indicating a strong demand for innovative assets [1][6] - The industry is experiencing a "survival of the fittest" phase, with many biotech firms facing operational challenges and some shutting down due to clinical trial failures [2][8] Mergers and Acquisitions - Boston Scientific has announced two major acquisitions: Valencia Technologies Corporation and Penumbra, with the latter being its largest acquisition in nearly 20 years [1][4] - GSK's acquisition of RAPT Therapeutics aims to leverage its global R&D capabilities to enhance the value of RAPT's pipeline [1][6] - The trend of M&A is driven by MNCs facing a "patent cliff," with an estimated $400 billion in revenue at risk over the next decade [4] Industry Dynamics - The demand for high-quality innovative assets is increasing, leading to a surge in business development (BD) and M&A activities in the biopharmaceutical sector [2][4] - The competitive landscape is shifting from product-based competition to pipeline and product integration capabilities among large pharmaceutical companies [7] - Biotech firms are increasingly viewed as valuable partners for MNCs, providing pathways for pipeline realization and cash flow enhancement [2][10] Challenges for Biotech - Nido Biosciences has ceased operations due to clinical trial failures, highlighting the risks faced by biotech companies in the current environment [2][8] - Financial instability and clinical setbacks are common reasons for biotech firms shutting down, with many struggling to secure funding [8][9] - The industry is witnessing a trend where companies must optimize their pipelines and manage resources effectively to survive [9][10] Future Outlook - The biopharmaceutical sector is expected to see continued M&A activity, particularly focusing on late-stage, lower-risk assets as uncertainties in key policies diminish [4] - Chinese biotech firms are increasingly engaging in BD collaborations with MNCs, driven by cost control and R&D efficiency advantages [10][12] - The industry is at a pivotal point, transitioning from quantity-driven growth to a focus on quality and value creation in the global health landscape [12]

Core Insights - The introduction of new pricing for lung cancer drugs, particularly the KRAS G12C inhibitors, has significantly reduced costs for patients, with prices dropping by nearly 70% for some medications [2][4][7] - The 2025 medical insurance directory includes 50 innovative drugs, with nearly half being cancer treatments, highlighting a focus on unmet clinical needs [2] - The competitive landscape for KRAS G12C inhibitors is intensifying, with companies now competing on clinical efficacy and commercial execution rather than just pricing [5][7][8] Pricing and Market Impact - The price of Fluorouracil has decreased from approximately 24,900 yuan to 5,790.4 yuan per box, resulting in a 68.87% reduction [7] - Patients previously faced annual treatment costs of 223,200 yuan, which can now be reduced to approximately 20,845.44 yuan after insurance reimbursement, saving over 200,000 yuan annually [4] - The entry of these drugs into the insurance system is expected to reshape market dynamics and increase competition among pharmaceutical companies [4][8] Competitive Landscape - The KRAS G12C inhibitors market is characterized by three main products: Fluorouracil, Goresir, and Gexoriser, all approved for similar indications, creating a "three-legged" competitive structure [6] - The market for KRAS G12C inhibitors is not overly saturated, with the mutation occurring in about 14% of non-small cell lung cancer cases, and approximately 4.3% in the Chinese population [6] - Companies are focusing on differentiating their products through clinical evidence and effective management of side effects to establish a preferred choice among doctors and patients [7][8] Future Directions - Companies are exploring combination therapies and expanding indications beyond non-small cell lung cancer to other cancers like colorectal and pancreatic cancer, which may significantly increase market potential [13] - The focus on overcoming drug resistance and enhancing efficacy through partnerships and global market strategies is seen as essential for long-term success [13] - The competitive focus is shifting towards who can provide better clinical outcomes and safety profiles, indicating a new phase in the market dynamics for KRAS G12C inhibitors [7][8]

Group 1 - Greenland crisis has seen a turnaround with a framework agreement reached between the US and NATO regarding Greenland, which could benefit the US and NATO member countries [5] - The European Parliament has indefinitely frozen the review of the EU-US trade agreement due to threats to EU sovereignty and territorial integrity [6] - The People's Bank of China is accelerating the construction of a cross-border payment system for the renminbi and implementing strict regulatory measures for payment institutions [7] Group 2 - The cosmetics market in China is projected to exceed 1.1 trillion yuan by 2025, with domestic brands capturing over 57% market share [23] - China has become the world's largest exporter of machine tools, surpassing Germany with a 21.6% share of global exports [24] - The successful trial of automatic formation operation for heavy-duty trains in China marks a significant change in railway freight control [25] Group 3 - SpaceX plans to complete its IPO by July this year, as stated by CEO Elon Musk [27] - Xibei Catering has completed its Series A financing, with new investors including Zhang Yong, founder of New Rongji [28] - Apple is set to transform Siri into its first chatbot product by the second half of 2026, utilizing Google's Gemini model [29] Group 4 - TSMC's 3nm production capacity is fully booked until 2027 due to surging demand from artificial intelligence [30] - China Nuclear Power and Alibaba have established a nuclear energy company with a registered capital of 250 million yuan [31] - The download volume of Alibaba's Qianwen series models has surpassed 1 billion, making it the first open-source large model to achieve this milestone [32]

Group 1 - The 19th Asian Financial Forum will be held on January 26-27 in Hong Kong, featuring executives from companies such as Geely Holdings, LONGi Green Energy, and Tencent [1][2] - The forum aims to strengthen Hong Kong's role as a global financial center and facilitate connections between international and mainland markets [1][4] - A discussion on "gold trading" will take place on the first day, featuring speakers from MKS PAMP and the World Gold Council to explore Hong Kong's position in Asian gold pricing and trading [1][4] Group 2 - The first Global Industry Summit will occur on January 27, focusing on high-growth sectors like AI, robotics, and biomedicine, discussing how financial services can drive innovation and long-term growth [2][3] - Key leaders from various industries will share insights on leveraging Hong Kong as a platform for expanding overseas business and strategies for foreign companies entering the mainland market [2][3] - The summit will include discussions on the latest trends in biomedicine and healthcare, featuring executives from Amgen and Merck, addressing industry challenges and opportunities for innovation [3][4] Group 3 - The forum will have over 140 financial officials, business leaders, and experts as speakers, with participation expected from over 3,600 attendees across 60 countries and regions [4] - Topics covered will include global economic outlook, investment strategies, asset and wealth management, trade financing, and financial technology [4]

Group 1 - The core viewpoint of the news is that the biotechnology sector in the US is experiencing a strong rebound, with significant gains in major biotech stocks after a period of decline, indicating a recovery in market sentiment and capital inflow [1] - The Shenzhen Component Index fell by 0.52% and the ChiNext Index dropped by 0.79%, while specific stocks like Revolution Medicines Inc surged over 28%, indicating a divergence in performance within the market [1] - The S&P Biotechnology ETF (159502) rose by 2.38%, with a trading volume of 0.57 billion yuan and a turnover rate of 2.42%, reflecting increased investor interest in the biotech sector [1] Group 2 - The S&P Biotechnology ETF (159502) tracks the S&P Biotechnology Select Industry Index, covering high-quality companies in the global biotechnology sector, making it suitable for both retail and professional investors [2] - The management and custody fees for the S&P Biotechnology ETF (159502) are 0.60% per year, which positions it as a long-term investment tool while also catering to the needs of active traders [2] - Despite the positive trends, the sector may face short-term pressure until an official interest rate cut occurs, highlighting the need for investors to remain cautious about potential downside risks [2]

瑞银将其对美国生物科技巨头安进的股票评级由"中性"上调至"买入"，目标价由317美元上调至380美 元，称其两款处于研发后期的产品——减肥药MariTide和心血管药物olpasiran——将驱动公司增长至 2030年。这一目标价较安进周二美股收盘价有近15%的上行空间。 ...

Core Viewpoint - The announcement of a $2.015 billion licensing deal for the KRAS inhibitor JAB-23E73 by GakoSi has generated significant investor interest, despite a notable drop in the company's stock price following the announcement [1][2]. Group 1: Business Development and Financials - GakoSi has entered into a business development agreement with AstraZeneca for the KRAS inhibitor JAB-23E73, which includes an upfront payment of $100 million and potential milestone payments of up to $1.915 billion [2][3]. - AstraZeneca will be responsible for all clinical development, regulatory submissions, and commercialization activities for JAB-23E73 outside of China [3]. - The funds received from this collaboration will be allocated primarily to research and development, with over 90% dedicated to advancing next-generation drug development [3]. Group 2: Product and Market Potential - JAB-23E73 targets various KRAS mutations and is currently in Phase I clinical trials for late-stage solid tumor patients in China and the U.S., with plans to expand indications to pancreatic cancer, non-small cell lung cancer, and colorectal cancer [2][3]. - KRAS mutations are prevalent in approximately 23% of cancer patients, with specific mutation rates of 32% in lung cancer, 50% in colorectal cancer, and 88% in pancreatic cancer [2]. Group 3: Competitive Landscape - GakoSi is positioned as a key player in the KRAS inhibitor market, utilizing a small molecule approach, while other companies like Revolution Medicines focus on molecular glue strategies [4][5]. - The KRAS G12C inhibitor market is highly competitive, with five approved drugs targeting this mutation, and GakoSi, along with other domestic firms, has opted for partnerships with larger pharmaceutical companies for commercialization [5]. Group 4: Market Reaction and Company Strategy - Following the announcement, GakoSi's stock price fell by over 10%, closing down 13.58%, which the company's chairman attributed to various market factors rather than the deal itself [1][4]. - The chairman emphasized the importance of focusing on research and development rather than being swayed by market fluctuations, advocating for a specialized approach in the biopharmaceutical sector [6].